Literature DB >> 30557420

In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years.

Gaetano Santulli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30557420     DOI： 10.7326/ACPJC-2018-169-12-067

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  6 in total

1.  In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes.

Authors:  Francesco Zaccardi; Alessandro Rizzi; Giovanna Petrucci; Flavia Ciaffardini; Luigi Tanese; Francesca Pagliaccia; Viviana Cavalca; Angela Ciminello; Aida Habib; Isabella Squellerio; Paola Rizzo; Elena Tremoli; Bianca Rocca; Dario Pitocco; Carlo Patrono
Journal:  Diabetes       Date:  2015-10-15       Impact factor: 9.461

2.  Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.

Authors:  Sameer D Saini; Philip Schoenfeld; A Mark Fendrick; James Scheiman
Journal:  Arch Intern Med       Date:  2008-08-11

3.  Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.

Authors:  Kirsten Bibbins-Domingo
Journal:  Ann Intern Med       Date:  2016-04-12       Impact factor: 25.391

4.  Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.

Authors:  John J McNeil; Rory Wolfe; Robyn L Woods; Andrew M Tonkin; Geoffrey A Donnan; Mark R Nelson; Christopher M Reid; Jessica E Lockery; Brenda Kirpach; Elsdon Storey; Raj C Shah; Jeff D Williamson; Karen L Margolis; Michael E Ernst; Walter P Abhayaratna; Nigel Stocks; Sharyn M Fitzgerald; Suzanne G Orchard; Ruth E Trevaks; Lawrence J Beilin; Colin I Johnston; Joanne Ryan; Barbara Radziszewska; Michael Jelinek; Mobin Malik; Charles B Eaton; Donna Brauer; Geoff Cloud; Erica M Wood; Suzanne E Mahady; Suzanne Satterfield; Richard Grimm; Anne M Murray
Journal:  N Engl J Med       Date:  2018-09-16       Impact factor: 91.245

5.  Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.

Authors:  J Michael Gaziano; Carlos Brotons; Rosa Coppolecchia; Claudio Cricelli; Harald Darius; Philip B Gorelick; George Howard; Thomas A Pearson; Peter M Rothwell; Luis Miguel Ruilope; Michal Tendera; Gianni Tognoni
Journal:  Lancet       Date:  2018-08-26       Impact factor: 79.321

Review 6.  Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs.

Authors:  Giuseppe Patti; Ilaria Cavallari; Felicita Andreotti; Paolo Calabrò; Plinio Cirillo; Gentian Denas; Mattia Galli; Enrica Golia; Ernesto Maddaloni; Rossella Marcucci; Vito Maurizio Parato; Vittorio Pengo; Domenico Prisco; Elisabetta Ricottini; Giulia Renda; Francesca Santilli; Paola Simeone; Raffaele De Caterina
Journal:  Nat Rev Cardiol       Date:  2019-02       Impact factor: 32.419
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.